A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00778336
Recruitment Status : Completed
First Posted : October 23, 2008
Results First Posted : April 26, 2011
Last Update Posted : October 17, 2014
Information provided by (Responsible Party):
Boston Scientific Corporation

October 22, 2008
October 23, 2008
February 22, 2011
April 26, 2011
October 17, 2014
January 2007
March 2010   (Final data collection date for primary outcome measure)
Change From Baseline to Final Angiographic Results [ Time Frame: Index Procedure ( pre-endovascular treatment and post-endovascular treatment) ]

From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms,each vessel was assigned a value by the treating physician:

  1. complete occlusion (> 90% occlusion);
  2. substantial occlusion (50-90% occlusion OR <50% occlusion and >3cm in length);
  3. partial occlusion (<50% occlusion AND <3cm in length);
  4. patent (Without visable thrombus or occlusion).

The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic value from the final value.

Evaluate the performance of the AngioJet midlength catheters [ Time Frame: Upon admission for procedure through 3 month follow up ]
Complete list of historical versions of study NCT00778336 on Archive Site
  • Rethrombosis [ Time Frame: 3 Month Follow Up ]
    The number of patients that had rethrombosed in the vessels treated during the index procedure (initial endovascular procedure).
  • Description of Treatments by Thrombotic Condition [ Time Frame: Index Procedure ]
    The # of patients that were exposed to each treatment at least once in the given thrombotic condition.
Not Provided
Not Provided
Not Provided
A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters
Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters
This registry collects observational data about how mid-length AngioJet catheters (ie XPEEDIOR and DVX models) are used in routine clinical practice.

The PEARL Registry collects real world data about mid-length AngioJet catheters to:

  • Characterize usage patterns, treatment approaches, and targeted vessels
  • Document treatment strategies, including specific techniques and concomitant therapies
  • Collect outcome data during initial hospitalization and at a 3-month follow-up phone call or visit
  • Evaluate the frequency of specific clinical events in relation to risk factors, diagnosis, and treatments provided
  • Identify treatment strategies that may optimize procedural and clinical outcomes, to facilitate development of treatment guidelines
  • Offer sites a valuable resource for tracking usage and performance of the AngioJet System at their institution

Information collected by the PEARL Registry is intended for educational and clinical research purposes only.

Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patient with peripheral thrombosis treated with a AngioJet mid-length catheter that is indicated for thrombosis removal.
  • Peripheral Vascular Diseases
  • Thrombosis
  • Venous Thrombosis
Not Provided
  • Limb Ischemia
    Patients presenting with limb ischemia for treatment
  • Deep Vein Thrombosis
    Patients presenting with deep vein thrombosis for treatment
  • Hemodialysis Access
    Patients presenting with thrombosed hemodialysis access for treatment
  • Other Thrombotic Conditions
    Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has been treated with a mid-length AngioJet catheter(defined as 90-120 cm in length)
  • Patient has provided appropriate authorization per institutional policy and procedure.

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Older Adult
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Boston Scientific Corporation
Boston Scientific Corporation
Not Provided
Principal Investigator: Lawrence R. Blitz, MD Chilton Memorial Hospital, Pompton Plains, NJ
Principal Investigator: Robert Lookstein, MD Mount Sinai School of Medicine, NYC, NY
Principal Investigator: Eugene Simoni, MD Samaritan Vascular Institute, Dayton, OH
Boston Scientific Corporation
October 2014